JP2016535020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535020A5 JP2016535020A5 JP2016525876A JP2016525876A JP2016535020A5 JP 2016535020 A5 JP2016535020 A5 JP 2016535020A5 JP 2016525876 A JP2016525876 A JP 2016525876A JP 2016525876 A JP2016525876 A JP 2016525876A JP 2016535020 A5 JP2016535020 A5 JP 2016535020A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- chain variable
- variable region
- seq
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019024364A JP6896781B2 (ja) | 2013-10-24 | 2019-02-14 | 安定した水性抗体製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895143P | 2013-10-24 | 2013-10-24 | |
| US61/895,143 | 2013-10-24 | ||
| PCT/US2014/061997 WO2015061584A1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019024364A Division JP6896781B2 (ja) | 2013-10-24 | 2019-02-14 | 安定した水性抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535020A JP2016535020A (ja) | 2016-11-10 |
| JP2016535020A5 true JP2016535020A5 (enExample) | 2017-11-24 |
| JP6483673B2 JP6483673B2 (ja) | 2019-03-13 |
Family
ID=52993565
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525876A Active JP6483673B2 (ja) | 2013-10-24 | 2014-10-23 | 安定した水性抗体製剤 |
| JP2019024364A Active JP6896781B2 (ja) | 2013-10-24 | 2019-02-14 | 安定した水性抗体製剤 |
| JP2021096239A Pending JP2021152034A (ja) | 2013-10-24 | 2021-06-09 | 安定した水性抗体製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019024364A Active JP6896781B2 (ja) | 2013-10-24 | 2019-02-14 | 安定した水性抗体製剤 |
| JP2021096239A Pending JP2021152034A (ja) | 2013-10-24 | 2021-06-09 | 安定した水性抗体製剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20150118249A1 (enExample) |
| EP (2) | EP3892288A1 (enExample) |
| JP (3) | JP6483673B2 (enExample) |
| KR (3) | KR20210041101A (enExample) |
| CN (4) | CN105611938B (enExample) |
| AU (4) | AU2014339984B2 (enExample) |
| BR (1) | BR112016008576B1 (enExample) |
| CA (1) | CA2926089C (enExample) |
| CY (1) | CY1125697T1 (enExample) |
| DK (1) | DK3060229T3 (enExample) |
| ES (1) | ES2893861T3 (enExample) |
| HR (1) | HRP20211371T1 (enExample) |
| HU (1) | HUE055919T2 (enExample) |
| LT (1) | LT3060229T (enExample) |
| MX (2) | MX388893B (enExample) |
| PL (1) | PL3060229T3 (enExample) |
| PT (1) | PT3060229T (enExample) |
| RS (1) | RS62419B1 (enExample) |
| RU (2) | RU2763787C2 (enExample) |
| SG (2) | SG10201803178UA (enExample) |
| SI (1) | SI3060229T1 (enExample) |
| SM (1) | SMT202100580T1 (enExample) |
| WO (1) | WO2015061584A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| AU2013256229A1 (en) * | 2012-05-03 | 2014-10-30 | Medimmune, Llc | Method for analyzing sample components |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| ES2744526T3 (es) | 2014-03-12 | 2020-02-25 | Prothena Biosciences Ltd | Anticuerpos anti-MCAM y métodos de uso asociados |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP4606820A3 (en) * | 2015-11-30 | 2025-10-29 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| ES2968923T3 (es) | 2016-08-10 | 2024-05-14 | Celltrion Inc | Preparación farmacéutica líquida estable de anticuerpo contra el virus de la gripe |
| AU2017345490B2 (en) | 2016-10-21 | 2022-07-07 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| CN113507938B (zh) * | 2019-03-29 | 2024-04-16 | 广东恒瑞医药有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| JP7718272B2 (ja) * | 2019-12-16 | 2025-08-05 | ニプロ株式会社 | 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス |
| CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
| KR20220152540A (ko) * | 2020-03-13 | 2022-11-16 | 삼성바이오에피스 주식회사 | 안정성이 증진된 액상 약제학적 조성물 |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| CA3204307A1 (en) * | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Anti-il5r antibody formulations |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6018032A (en) * | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| JP2006502116A (ja) * | 2002-07-12 | 2006-01-19 | メダレックス， インク． | タンパク質の酸化分解を防ぐ方法及び組成物 |
| CN100448495C (zh) * | 2003-05-26 | 2009-01-07 | 白又寅 | 一次性注射器 |
| DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
| GEP20125628B (en) * | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| DK3072525T3 (en) | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| SG2014011365A (en) * | 2008-09-19 | 2014-05-29 | Hoffmann La Roche | Novel antibody formulation |
| CA2754528A1 (en) * | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
| NZ613809A (en) * | 2009-05-04 | 2015-02-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| BR112014009031A2 (pt) * | 2011-10-18 | 2017-05-09 | Coherus Biosciences Inc | formulações de etanercept estabilizadas com íons de metais |
| EP2771358A4 (en) * | 2011-10-26 | 2015-08-26 | Bio Rad Laboratories | ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY |
| CA2951856A1 (en) * | 2011-10-28 | 2013-05-02 | Integritybio Inc. | Protein formulations containing amino acids |
| US20140328839A1 (en) * | 2011-11-01 | 2014-11-06 | Medlmmune, Llc | Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma |
| KR102337599B1 (ko) * | 2013-08-12 | 2021-12-10 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 |
| WO2015023504A1 (en) * | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| EP3892288A1 (en) * | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
-
2014
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/en active Pending
- 2014-10-23 CN CN201480055263.0A patent/CN105611938B/zh active Active
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/en active Active
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Ceased
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active Active
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/en not_active Ceased
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 CA CA2926089A patent/CA2926089C/en active Active
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 CN CN202411964617.5A patent/CN119971024A/zh active Pending
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 MX MX2016004605A patent/MX388893B/es unknown
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 SM SM20210580T patent/SMT202100580T1/it unknown
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active Active
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2014-10-23 RU RU2021137159A patent/RU2021137159A/ru unknown
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
- 2019-03-11 US US16/298,474 patent/US20190201535A1/en active Pending
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595B2/en active Active
-
2025
- 2025-02-04 US US19/045,166 patent/US20250170245A1/en active Pending
- 2025-09-12 AU AU2025230794A patent/AU2025230794A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535020A5 (enExample) | ||
| AU2022291595B2 (en) | Stable, aqueous antibody formulations | |
| JP7035119B2 (ja) | 安定な抗ｉｆｎａｒ１製剤 | |
| JP2018162295A (ja) | 医薬製剤 | |
| JP2017160208A5 (enExample) | ||
| JP7783051B2 (ja) | 抗ａｎｇｐｔｌ３抗体を含有する安定化製剤 | |
| TW201641104A (zh) | Ｉｌ－１７抗體之醫藥產品及穩定之液體組合物 | |
| JP2018507202A (ja) | モノクローナル抗体のための安定的な液体製剤 | |
| JP2019520316A5 (enExample) | ||
| JP2020502219A5 (enExample) | ||
| JP2019520390A (ja) | 抗体製剤 | |
| JP2023511080A (ja) | 安定な抗体製剤 | |
| JP2020502218A5 (enExample) | ||
| TWI760345B (zh) | 抗體調配物 | |
| KR20230121797A (ko) | 항-il5r 항체 제형 | |
| HK1227741B (en) | Stable, aqueous antibody formulations |